Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voriconazole inhalation powder versus oral voriconazole for acute invasive pulmonary aspergillosis
2021-006633-19Phase 2Completed
- Sponsor
- TFF Pharmaceuticals
- Start
- Jun 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Acute Invasive Aspergillosis and aspergillosis comparing Voriconazole inhalation powder with Oral voriconazole tablets standard of care (2 arms). Primary endpoint: Safety and tolerability. Started Jun 2022; status: completed.
02
Drugs
voriconazole
03
Conditions
Acute Invasive Aspergillosisaspergillosis
Beyond the preview
Go deeper on 2021-006633-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006633-19.